A novel targeted approach to delineate a role for estrogen receptor-β in ameliorating murine mammary tumor-associated neuroinflammation

• Published in: Endocrine 2022-03, Vol.75 (3), p.949-958
• Main Authors: Grant, Corena V., Russart, Kathryn L. G., Pyter, Leah M.
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Anti-inflammatory agents; Aromatase; Brain; Breast cancer; Breast Neoplasms - complications; Cognitive ability; Cortex (frontal); Cytokines; Diabetes; Disease Models, Animal; Endocrinology; Estrogen Receptor alpha - metabolism; Estrogen Receptor beta - agonists; Estrogen Receptor beta - genetics; Estrogen Receptor beta - metabolism; Estrogen receptors; Estrogens; Estrogens - metabolism; Female; Humanities and Social Sciences; Hypothalamus; Inflammation; Internal Medicine; Mammary gland; Mammary Neoplasms, Experimental - complications; Medicine; Medicine & Public Health; Menopause; Mice; multidisciplinary; Nervous system; Neuroinflammatory Diseases - etiology; Neuroinflammatory Diseases - metabolism; Neurosciences; Original Article; Ovariectomy; Patients; Post-menopause; Science; Tumors
• ISSN: 1355-008X; 1559-0100
• DOI: 10.1007/s12020-021-02931-7

Purpose Circulating estrogens in breast cancer patients and survivors are often extremely low due to menopause and estrogen-reducing cancer treatments. Simultaneously, circulating inflammatory markers, and inflammatory proteins in brains of rodent tumor models, can be elevated and correlate with debilitating neurological and psychological comorbidities. Because estrogen has anti-inflammatory properties in the brain, we hypothesized that mammary tumor-induced neuroinflammation is driven, in part, by reduced brain estrogen signaling. Methods An ovariectomized mouse model of postmenopausal breast cancer utilizing the ERα-positive 67NR mammary tumor cell line was used for these experiments. A novel, orally bioavailable, and brain penetrant ERβ agonist was administered daily via oral gavage. Following treatment, estrogen-responsive genes were measured in brain regions. Central and circulating inflammatory markers were measured via RT-qPCR and a multiplex cytokine array, respectively. Results We present novel findings that peripheral mammary tumors alter estrogen signaling genes including receptors and aromatase in the hypothalamus, hippocampus, and frontal cortex. Mammary tumors induced peripheral and central inflammation, however, pharmacological ERβ activation was not sufficient to reduce this inflammation. Conclusions Data presented here suggest that compensating for low circulating estrogen with ERβ brain activation is not sufficient to attenuate mammary tumor-induced neuroinflammation, and is therefore not a likely candidate for the treatment of behavioral symptoms in patients. The novel finding that mammary tumors alter estrogen signaling-related genes is a clinically relevant advancement to the understanding of how peripheral tumor biology modulates neurobiology. This is necessary to predict and prevent behavioral comorbidities (e.g., cognitive impairment) prevalent in cancer patients and survivors.